Orforglipron (Capsules)
Non-Peptide Oral GLP-1 Receptor Agonist
CAS: 2212020-52-3
Formula: C40H47F3N8O5
M.W.: 776.8549 g/mol
Purity: 99%+ HPLC Verified
Ref No.: ORF-0006TA
For Research Use Only (RUO)
Not for human or veterinary use.
Orforglipron (Capsules)
Category
GLP / Metabolic Research
CAS Number
2212020-52-3
Form Factor
Capsules
In stock, ready to ship
Ships same day before 12pm PST
Products are shipped in capsule form.
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist investigated for receptor activation and downstream metabolic signaling. Research examines concentration-dependent metabolic endpoints, enteral bioavailability, pharmacokinetic behavior, and room-temperature stability in experimental incretin-pathway protocols.
Description
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist investigated for receptor activation and downstream metabolic signaling. Research examines concentration-dependent metabolic endpoints, enteral bioavailability, pharmacokinetic behavior, and room-temperature stability in experimental incretin-pathway protocols.Chemical Information
CAS Number
2212020-52-3
Purity
99%+ HPLC Verified
Molecular Formula
C40H47F3N8O5
Molar Mass
776.8549 g/mol
Form Factor
Capsules
Synonyms
Research Applications
- Pharmaceutical Sciences: Orforglipron is investigated as a non-peptide, small-molecule GLP-1 receptor agonist. Research examines its receptor-binding mode, activation kinetics, signaling selectivity, and biased-agonism profile relative to peptide-based GLP-1 receptor agonists.
- Metabolic Research: Encapsulated orforglipron formulations are studied in experimental models of metabolic dysregulation. Investigations characterize concentration-dependent adipose-tissue responses, glycemic biomarkers, energy-balance signaling, and metabolic adaptation during extended observation periods.
- Drug-Delivery Research: Orforglipron is evaluated for room-temperature stability, gastrointestinal transport, and enteral bioavailability. Research focuses on physicochemical stability, pharmacokinetic behavior, absorption kinetics, and the influence of gastrointestinal conditions on systemic distribution.
- Pharmacology Research: Orforglipron is studied to characterize concentration-response relationships across adipose-tissue, glycemic, and GLP-1 receptor-signaling endpoints.
Storage Conditions
Unreconstituted
Store at -20°C to 4°C (freezer or refrigerator). Stable for 24+ months.
Reconstituted
Refrigerate at 2–8°C. Use within 30 days for optimal stability.
Avoid
Repeated freeze-thaw cycles, direct sunlight, and temperatures above 25°C.
Safety & Compliance
- Wear nitrile gloves and safety goggles when handling research compounds.
- Work in a clean, controlled environment (laminar flow hood recommended).
- Dispose of sharps and used materials in approved biohazard containers.
- This product is for laboratory research use only (RUO) — not for human or veterinary use.
Quality Assurance Standards
Each production lot is subjected to rigorous analytical evaluation to meet pharmaceutical-grade specifications. Full testing results and procedural documentation are furnished through the accompanying Certificate of Analysis (COA) with every shipment.
Certificate of Analysis
Latest COA for Orforglipron (Capsules) — independently tested via HPLC and Mass Spectrometry.
Testing Methodology
Every batch undergoes a multi-stage analytical pipeline before release. Results are compiled into the Certificate of Analysis (COA) included with each order.
- • HPLC — High-Performance Liquid Chromatography confirms peptide purity ≥98%.
- • Mass Spectrometry — Validates molecular identity and correct sequence.
- • Endotoxin (LAL) — Limulus Amebocyte Lysate assay ensures endotoxin levels are within safe limits.
- • Sterility — Microbial contamination testing per USP standards.
Learn More About Peptides
Explore our research library covering purity, synthesis, storage, solubility, and more.
Research Database
Browse peer-reviewed studies, clinical trials, and scientific sources behind our peptide resources.
You May Also Like
-
$124.99
Semax (Spray)
GH / Neuro / Misc ResearchThis product has multiple variants. The options may be chosen on the product page View Details -
$99.99
NAD+ (Spray)
GH / Neuro / Misc ResearchThis product has multiple variants. The options may be chosen on the product page View Details -
$109.99
BPC-157 (Spray)
Regenerative ResearchThis product has multiple variants. The options may be chosen on the product page View Details -
$124.99
Selank (Spray)
GH / Neuro / Misc ResearchThis product has multiple variants. The options may be chosen on the product page View Details
Popular Product
Popular Product
Popular Product
Popular Product
Description
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist investigated for receptor activation and downstream metabolic signaling. Research examines concentration-dependent metabolic endpoints, enteral bioavailability, pharmacokinetic behavior, and room-temperature stability in experimental incretin-pathway protocols.Chemical Information
CAS Number
2212020-52-3
Purity
99%+ HPLC Verified
Molecular Formula
C40H47F3N8O5
Molar Mass
776.8549 g/mol
Form Factor
Capsules
Synonyms
Research Applications
- Pharmaceutical Sciences: Orforglipron is investigated as a non-peptide, small-molecule GLP-1 receptor agonist. Research examines its receptor-binding mode, activation kinetics, signaling selectivity, and biased-agonism profile relative to peptide-based GLP-1 receptor agonists.
- Metabolic Research: Encapsulated orforglipron formulations are studied in experimental models of metabolic dysregulation. Investigations characterize concentration-dependent adipose-tissue responses, glycemic biomarkers, energy-balance signaling, and metabolic adaptation during extended observation periods.
- Drug-Delivery Research: Orforglipron is evaluated for room-temperature stability, gastrointestinal transport, and enteral bioavailability. Research focuses on physicochemical stability, pharmacokinetic behavior, absorption kinetics, and the influence of gastrointestinal conditions on systemic distribution.
- Pharmacology Research: Orforglipron is studied to characterize concentration-response relationships across adipose-tissue, glycemic, and GLP-1 receptor-signaling endpoints.
Storage Conditions
Unreconstituted
Store at -20°C to 4°C (freezer or refrigerator). Stable for 24+ months.
Reconstituted
Refrigerate at 2–8°C. Use within 30 days for optimal stability.
Avoid
Repeated freeze-thaw cycles, direct sunlight, and temperatures above 25°C.
Safety & Compliance
- Wear nitrile gloves and safety goggles when handling research compounds.
- Work in a clean, controlled environment (laminar flow hood recommended).
- Dispose of sharps and used materials in approved biohazard containers.
- This product is for laboratory research use only (RUO) — not for human or veterinary use.
Quality Assurance Standards
Each production lot is subjected to rigorous analytical evaluation to meet pharmaceutical-grade specifications. Full testing results and procedural documentation are furnished through the accompanying Certificate of Analysis (COA) with every shipment.
Certificate of Analysis
Latest COA for Orforglipron (Capsules) — independently tested via HPLC and Mass Spectrometry.
Testing Methodology
Every batch undergoes a multi-stage analytical pipeline before release. Results are compiled into the Certificate of Analysis (COA) included with each order.
- • HPLC — High-Performance Liquid Chromatography confirms peptide purity ≥98%.
- • Mass Spectrometry — Validates molecular identity and correct sequence.
- • Endotoxin (LAL) — Limulus Amebocyte Lysate assay ensures endotoxin levels are within safe limits.
- • Sterility — Microbial contamination testing per USP standards.
Learn More About Peptides
Explore our research library covering purity, synthesis, storage, solubility, and more.
Research Database
Browse peer-reviewed studies, clinical trials, and scientific sources behind our peptide resources.
